Avance Biosciences is excited to announce its participation in the upcoming WRIB Conference, taking place from April 7 – 11, 2025, in New Orleans, LA. This premier event is focused advancing regulatory science, innovation, and best practices in biologics and biosimilars, bringing together experts to discuss the latest developments and challenges in the field.
Avance Biosciences: Advancing Bioanalysis with Cutting-Edge Solutions
At Avance Biosciences, we are dedicated to advancing life sciences through comprehensive bioanalytical services, tailored to support the development of Small and Large molecules, Biomarkers, Gene and Cell therapies, and Biologic Characterization Assays. With deep expertise in Bioanalytical testing, Specialized Assays, and Emerging Therapeutic approaches, we provide precise, reliable data to accelerate your research and clinical trials.
Our Key Services Include:
- Advanced techniques including LBA, Flow Cytometry, qPCR, and ddPCR as well as innovative technologies such as NGS, LC-MS/MS, and Hybrid LBA/LC-MS for the most accurate analysis.
- Expertise in Peptides, Oligonucleotides, and Emerging Modalities, driving forward cutting-edge therapies.
- Custom solutions designed to address emerging technologies and meet the evolving needs of the biotech and pharmaceutical industries.
“We’re thrilled to participate in WRIB 2025, where our team will highlight our cutting-edge solutions in the biologics and biosimilars space. This conference presents a unique platform for collaboration and advancing our knowledge of regulatory science and innovation. Avance is dedicated to supporting biopharmaceutical companies by offering comprehensive testing and analytical services that facilitate product development, ensure regulatory compliance, and drive success in the rapidly evolving biologics sector.

Chris Hebel – VP of Marketing at Avance Biosciences.